In a Phase III randomized trial of adjuvant chemotherapy using the platinum-based PELF (platinum, etoposide, leucovorin, and fluorouracil) regimen after potentially curative surgery for gastric cancer, no significant improvement in disease-free or overall survival was observed. The findings are discussed in the context of other trials and highlight the uncertainty surrounding the appropriate approach for the treatment of patients in this setting.Source:
Costanzo FD, et al. Adjuvant chemotherapy in completely resected gastric cancer: A randomized Phase III trial conducted by GOIRC. JNCI. 2008;100:388-398.